Lynda Charters

Though there is no current FDA-approved treatment, lotilaner ophthalmic solution, 0.25%, is the first drug designed to treat and target the underlying cause of Demodex blepharitis.

Because the disease is vision-threatening, the investigators retrospectively reviewed the demographic, clinical, and surgical data from the cases of patients who required additional CXL.

Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.

In this first study to provide an in-depth analysis of the retinal proteins, researchers conducted histopathologic and biochemical studies of postmortem retina and brain tissues from 86 human donors.

Self-reported survey data “showed that a majority reported reductions in visual recognition and navigation abilities,” the researchers reported.

Investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.

Researchers retrospectively analyzed the longitudinal clinical data of 117 eyes of 106 Caucasian patients with high myopia MNV treated with intravitreal bevacizumab injections.

Conference aims to promote professional education and scientific development in corneal ectasias.

Investigators evaluated and compared the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed between 2 hydrophobic acrylic intraocular lenses (IOLs).

Smaller corneal incisions made during cataract surgery are linked with better visual outcomes and less frequent postoperative endophthalmitis.

The FDA issued an update to the warning issued early in February and recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment, and the firm agreed to initiate a recall.

The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

The trial showed no added benefit of nesvacumab and aflibercept combination therapy over aflibercept monotherapy.

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.

Second global virtual event on myopia management scheduled for February 16, 2023.

Researchers found that the use of atropine drops after glaucoma surgery may impact vision and prolong rehabilitation time.

Researchers found that prompt intervention may improve the prognosis of fungal endophthalmitis caused by contaminated medical products.

The main outcomes were the national prevalence of impaired presenting distance VA, presenting near VA, and contrast sensitivity.

The research team retrospectively studied the long-term corneal endothelial cell changes and visual outcomes after this iris-fixated phakic IOL was explanted in patients with endothelial damage and investigated any potential predictors of endothelial injury.

A recent study showed herpesvirus DNA in a high percentage of corneal grafts after transplantation.

New research identifies potential new TED biomarkers based on the disease activity or inactivity.

Though rare, visual decreases can occur within 1 day postoperatively after phacoemulsification surgery.

A multicenter US study revealed that the long-term use of metformin to treat diabetes and lifestyle changes in patients with diabetes were not associated with the risk of age-related macular degeneration (AMD).

Researchers reported that the preclinical detectable phase for OAG is about 10 years.

The glaucoma field is on the move with significant innovations in a number of treatment areas. Experts discussed the various technologies at the Optometry Times 2022 EyeCon meeting in Marco Island, Florida.

Three experts in myopia control convened at the Optometry Times EyeCon meeting to discuss methods to control this burgeoning global epidemic.

Panel discusses the highs and lows of treating patients with this condition.

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.